Elizabeth Warren

Thank you, Chair Collins. I want to thank you for holding this hearing today. This is really important.

Or we can play it safe, keep the threshold where it is, and rely on the Fed to follow the law and tailor the risks--tailor the regulations to the risks that are posed by different large financial institutions.

To me, this is an easy decision. We can raise the threshold and cut loose half or more of the biggest banks in the country and just hope they do not make the same mistakes that they made in 2008 when they nearly brought down the whole…

Wale is a miracle worker. He works hard. He is smart. He manages people and projects with amazing skill.

I hope that everyone on this Committee will support him and that he gets an up-or-down vote from the Senate very quickly.

This tougher scrutiny is designed to focus the attention of the regulators on where the risk is.

He really is a remarkable guy.

I want to know if you will commit to working with me to make sure that both the regulators and the financial industry are doing everything possible to shut down financing for human trafficking.

If we walk away from this deal, is it more likely or is it less likely that our international partners will continue tough sanctions?

A better path forward is to accept this agreement and maintain unity with our international partners.

I have legislation to ensure that the Treasury Department and other financial regulators work more closely with financial institutions to stop human traffickers' use of the banking system.

If we back out of this deal, the international coalition that has made sanctions so effective would fracture.

We've got to have those. I get that you want to get those. We also need a plan in place that's going to educate physicians, that's going to educate the public because there really will be confidence that this work.

We've got to create a market here that works.

I'm concerned that misunderstandings about biosimilars could hamper their uptake in the market.

We know from the very established generic drug market that it suffers from severe misperceptions here.

The real question that I'm pushing on is that it is time now to get this done.

But, the question is it's been 5 years now?

Biologic drugs, complex products like enzymes and antibodies, are great medical achievements that allow people to live longer, healthier lives.

The Federal Government has spent more than $30 billion supporting the adoption of electronic health records, and we did it because we know that exchanging health information and providing patients with access to their data can reduce…

In 2009, Congress expanded those rights with the HITECH Act, encouraging hospitals and doctors to set up electronic health record systems.

In 1996, when Congress passed the Health Insurance Portability and Accountability Act, or HIPAA, it set important privacy standards, and it made clear that patients have a right to see their own medical records.

Making sure that patients have access to their own information is also the best way to engage patients in their own healthcare and to improve outcomes.

Patients want access to their own health data, and they should have an easy way to do that.

I remain very concerned that these policies leave the door open for dangerous antibiotic regimens to continue.